Cd30 Expression Defines A Novel Subgroup Of Diffuse Large B-Cell Lymphoma With Favorable Prognosis And Distinct Gene Expression Signature: A Report From The International Dlbcl Rituximab-Chop Consortium Program Study
Shimin Hu,Zijun Y Xu-Monette,Aarthi Balasubramanyam,Ganiraju C Manyam,Carlo Visco,Alexander Tzankov,Wei-min Liu,Roberto N Miranda,Li Zhang,Santiago Montes-Moreno,Karen Dybkær,April Chiu,Attilio Orazi,Youli Zu,Govind Bhagat,Kristy L Richards,Eric D Hsi,William W L Choi,J Han van Krieken,Qin Huang,Jooryung Huh,Weiyun Ai,Maurilio Ponzoni,Andrés J M Ferreri,Xiaoying Zhao,Jane N Winter,Mingzhi Zhang,Ling Li,Michael B Møller,Miguel A Piris,Yong Li,Ronald S Go,Lin Wu,L Jeffrey Medeiros,Ken H Young
DOI: https://doi.org/10.1182/blood-2012-10-461848
IF: 20.3
2013-01-01
Blood
Abstract:CD30, originally identified as a cell-surface marker of Reed-Sternberg and Hodgkin cells of classical Hodgkin lymphoma, is also expressed by several types of non-Hodgkin lymphoma, including a subset of diffuse large B-cell lymphoma (DLBCL). However, the prognostic and biological importance of CD30 expression in DLBCL is unknown. Here we report that CD30 expression is a favorable prognostic factor in a cohort of 903 de novo DLBCL patients. CD30 was expressed in similar to 14% of DLBCL patients. Patients with CD30(+) DLBCL had superior 5-year overall survival (CD30(+), 79% vs CD30(-), 59%; P = .001) and progression-free survival (P = .003). The favorable outcome of CD30 expression was maintained in both the germinal center B-cell and activated B-cell subtypes. Gene expression profiling revealed the upregulation of genes encoding negative regulators of nuclear factor kappa B activation and lymphocyte survival, and downregulation of genes encoding B-cell receptor signaling and proliferation, as well as prominent cytokine and stromal signatures in CD30(+) DLBCL patients, suggesting a distinct molecular basis for its favorable outcome. Given the superior prognostic value, unique gene expression signature, and significant value of CD30 as a therapeutic target for brentuximab vedotin in ongoing successful clinical trials, it seems appropriate to consider CD30(+) DLBCL as a distinct subgroup of DLBCL. (Blood. 2013;121(14):2715-2724)